Mid career · publishing since 2016Rising activity
Prostate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesProstate Cancer Diagnosis and TreatmentCancer Genomics and Diagnostics
Publications
112
Citations
991
Est. group size
~42
Recurring co-author estimate
Active years
11
Publishing since 2016
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 991p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 20.6p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~36 · 2% small-team papers (≤3 authors) · across 9 venues
Publication cadence
Publications per year over the last 10 years — averaging 20.6/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Supplementary Table S4 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Figure S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Figure S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Figure S4 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S10 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Data from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Figure S1 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S9 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S12 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S11 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
- Supplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2026
Publishes in
- Cancer Research×6
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Cell Reports Medicine×2
- Clinical & Experimental Metastasis×2
- Journal of the American College of Surgeons×2
Similar researchers
By research-topic overlap
- Xiangnan Guan
Medicine · The Ohio State University
- Scott A. Tomlins
Medicine · University of Michigan
- Li Zhang
Medicine · University of Michigan
- Sean S. Park
Medicine · University of Michigan
- Timothy D. Gauntner
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile